Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

P921

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q37498738

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@en

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@en-gb

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@nl

type

Item

label

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@en

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@en-gb

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@nl

prefLabel

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@en

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@en-gb

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@nl

P1154

Q37498738-2C915425-9E68-4EE5-B20D-F0A83EB8B4CD

P1433

Q37498738-D0C26AE9-5C28-45A6-A5F1-283483D069E0

P1476

Q37498738-8ADA7B32-9759-4707-A21E-F88BCAB709AE

P2093

Q37498738-09998F3C-7BB5-4F2C-A7C6-2EDD50845E26

Q37498738-2D7CD743-9206-4435-9DAD-AE0708AE2EAB

Q37498738-2E2966B5-05D4-4F19-9281-BAE86E6F982E

Q37498738-5AA1B629-2177-43AC-B895-924F17759F18

Q37498738-5EDED980-294F-4D13-A74F-D912A8E97B0A

Q37498738-6700EAB4-8B4F-488C-AE7B-7C7A7730ADAD

Q37498738-7885BC92-1D50-4C62-A2EB-E41145504D16

Q37498738-7DBA84BA-46D2-4220-A590-92466BBA3568

Q37498738-E5CD3BB3-68D2-4AF9-8DC6-AE62C9028F7F

Q37498738-E6E6E1DF-6B9A-4B2B-A6E5-F5D0D1C48B0E

P2507

Q37498738-5E815F91-2A6D-4561-87EE-98E0AFD56CE3

P2860

Q37498738-2F7595CF-E9E5-417B-94F9-A0132EB381D4

Q37498738-39613085-0234-4C28-A77D-7A595B719E00

Q37498738-39CEADA3-B0BC-425C-A4DA-39993F97F019

Q37498738-4E9BD00F-2B89-4179-9236-9B0D168F8E46

Q37498738-56D8E809-5ADB-4463-B5AF-B6546767BA89

Q37498738-58492A06-69AC-4339-98DA-FF8FE474B005

Q37498738-5CA5E702-F2A0-47A0-8B3E-E572275CD0E2

Q37498738-61BB4A6F-AF0F-4610-AF00-CAB0C0EB4DCC

Q37498738-6AC717B4-9637-4E3F-AAFD-CAF69048481F

Q37498738-7026E4A1-CE89-4E71-9A58-FBF49BD03456

P2888

Q37498738-901EE0AE-2F91-4D50-91FF-2A78C53CE13D

P304

Q37498738-4ABC7D06-F305-47DB-815E-D65AD48FA798

P31

Q37498738-A4ACF9E0-9897-4630-9211-67BB3BDC9C1A

P356

Q37498738-788148A5-F524-477F-8FB4-513C33090728

P433

Q37498738-8B043F68-68E2-415A-AFEB-D792A32890E0

P478

Q37498738-5E0ACD67-B948-4707-9E2C-37D51FF163AB

P50

Q37498738-2CFB9B61-D05B-4838-914B-54BA8CB43312

Q37498738-78F8AB50-3BF0-43F7-BC4B-B447A65C58D7

Q37498738-EFB613D8-8677-4AD7-A650-8D057617371E

Q37498738-F4B3C111-DA79-46D5-8C66-F98C6C5CC820

Q37498738-FDC04503-D5BE-47A2-B686-E64974D01ED1

P5530

Q37498738-F53EA6F6-2625-485B-A5F1-2671E10DE379

P577

Q37498738-616C2044-7B8E-4E27-9B91-780AF9AD6AAE

P6179

Q37498738-94FA9A88-6F6F-4324-9CEF-C8ADC3EEF983

P6409

Q37498738-70481F8D-4C95-41C4-BC3D-C26C07B57D46

P698

Q37498738-6A9CB9DF-AD9A-4F71-BFDF-65B25DC04CA6

P932

Q37498738-01AA2653-ACC7-455B-BE5C-578BB937D571

P953

Q37498738-1D595A41-399C-4A6D-A79B-DB655D6988AA

P356

S13075-016-1190-Z

P1154

2-s2.0-85003604956

http://www.w3.org/2001/XMLSchema#string

P1433

Arthritis Research and Therapy

P1476

Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

@en

P2093

Alice Courties

http://www.w3.org/2001/XMLSchema#string

Bineta Ly

http://www.w3.org/2001/XMLSchema#string

Edward M Vital

http://www.w3.org/2001/XMLSchema#string

Elodie Rivière

http://www.w3.org/2001/XMLSchema#string

Gianfranco Ferraciolli

http://www.w3.org/2001/XMLSchema#string

Houria Hendel Chavez

http://www.w3.org/2001/XMLSchema#string

Jérémie Sellam

http://www.w3.org/2001/XMLSchema#string

Paul-Olivier Rouzaire

http://www.w3.org/2001/XMLSchema#string

Xavier Mariette

http://www.w3.org/2001/XMLSchema#string

Yassine Taoufik

http://www.w3.org/2001/XMLSchema#string

P2507

Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.

P2860

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

Targeting IL-33 in autoimmunity and inflammation

Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial.

IL-10-producing regulatory B cells induced by IL-33 (Breg(IL-33)) effectively attenuate mucosal inflammatory responses in the gut.

IL-33 regulates TNF-α dependent effects in synovial fibroblasts.

IL-33 exacerbates antigen-induced arthritis by activating mast cells.

Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency.

Disease-associated functions of IL-33: the new kid in the IL-1 family.

Alarmins in tendinopathy: unravelling new mechanisms in a common disease.

Personalized medicine: predicting responses to therapy in patients with RA.

P2888

s13075-016-1190-z

P304

294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13075-016-1190-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P5530

14749676

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011006503

http://www.w3.org/2001/XMLSchema#string

P6409

78816231

http://www.w3.org/2001/XMLSchema#string

P698

27964756

http://www.w3.org/2001/XMLSchema#string

P932

5154136

http://www.w3.org/2001/XMLSchema#string

P953

108079